Bausch + Lomb acquires Elios Vision to expand minimally invasive glaucoma treatment portfolio
Bausch + Lomb Corporation announced its acquisition of Elios Vision, Inc., the developer of the ELIOS procedure—the first clinically validated minimally invasive glaucoma surgery (MIGS) technique using an excimer laser.
The ELIOS procedure offers a minimally invasive, implant-free approach to reducing intraocular pressure, often in conjunction with cataract surgery.
“ELIOS is a precision, non-thermal laser-based procedure that supports streamlined care for glaucoma patients,” said Dr. Ike K. Ahmed, in a press release. He highlighted the potential of this technology to enhance patient outcomes and quality of life.
The acquisition also positions Bausch + Lomb to expand ELIOS’s reach globally. The technology, already CE-marked and available in the European Union, is in the process of gaining FDA approval for the U.S. market.
Elliot Friedman, former CEO of Elios Vision, emphasized the potential of the collaboration: “Combining cataract and glaucoma treatments could become the new standard of care with Bausch + Lomb’s extensive global presence.”
This acquisition reflects Bausch + Lomb’s commitment to advancing eye care technologies as glaucoma cases are projected to rise by 47% between 2020 and 2040.
Read the full press release here.
Related Content
